| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Adam Wysokiński, Jakub Kaźmierski, Iwona Kłoszewsk. Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy. Metabolic brain disease. vol 30. issue 2. 2016-03-01. PMID:25034457. |
serum levels of agrp protein in patients with schizophrenia on clozapine monotherapy. |
2016-03-01 |
2023-08-13 |
human |
| Adam Wysokiński, Jakub Kaźmierski, Iwona Kłoszewsk. Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy. Metabolic brain disease. vol 30. issue 2. 2016-03-01. PMID:25034457. |
the aim of the study was to find out if agrp level in subjects with schizophrenia on clozapine monotherapy is higher compared with healthy controls. |
2016-03-01 |
2023-08-13 |
human |
| Memduha Aydin, Bilge Cetin Ilhan, Saliha Calisir, Seda Yildirim, Ibrahim Ere. Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports. Therapeutic advances in psychopharmacology. vol 6. issue 1. 2016-02-25. PMID:26913176. |
clozapine is a second-generation antipsychotic used for treatment-resistant schizophrenia. |
2016-02-25 |
2023-08-13 |
Not clear |
| Antonio Bruno, Rocco Zoccali, Paolo Micali Bellinghieri, Gianluca Pandolfo, Pasquale De Fazio, Edoardo Spina, Maria Rosaria A Muscatell. Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. Journal of clinical psychopharmacology. vol 34. issue 5. 2016-02-24. PMID:25118083. |
reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. |
2016-02-24 |
2023-08-13 |
Not clear |
| Antonio Bruno, Rocco Zoccali, Paolo Micali Bellinghieri, Gianluca Pandolfo, Pasquale De Fazio, Edoardo Spina, Maria Rosaria A Muscatell. Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. Journal of clinical psychopharmacology. vol 34. issue 5. 2016-02-24. PMID:25118083. |
the present 12-week open-label uncontrolled trial was aimed to explore the efficacy of reboxetine add-on pharmacotherapy on clinical symptoms and cognitive functioning in 15 patients with schizophrenia with suboptimal response (mean [sd] brief psychiatric rating scale baseline total score, 32.2 [5.4]) despite receiving clozapine monotherapy at the highest tolerated dosage. |
2016-02-24 |
2023-08-13 |
Not clear |
| Antonio Bruno, Rocco Zoccali, Paolo Micali Bellinghieri, Gianluca Pandolfo, Pasquale De Fazio, Edoardo Spina, Maria Rosaria A Muscatell. Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. Journal of clinical psychopharmacology. vol 34. issue 5. 2016-02-24. PMID:25118083. |
after bonferroni correction, changes at the calgary depression scale for schizophrenia and at the verbal fluency task were not further confirmed.the results obtained indicate that reboxetine seemed to be scarcely effective for reducing clinical symptoms in patients with schizophrenia who have had an incomplete clinical response to clozapine. |
2016-02-24 |
2023-08-13 |
Not clear |
| Tyler S Kaster, Danilo de Jesus, Natasha Radhu, Faranak Farzan, Daniel M Blumberger, Tarek K Rajji, Paul B Fitzgerald, Zafiris J Daskalaki. Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. Schizophrenia research. vol 165. issue 2-3. 2016-02-22. PMID:25957485. |
clozapine potentiation of gaba mediated cortical inhibition in treatment resistant schizophrenia. |
2016-02-22 |
2023-08-13 |
Not clear |
| Clare Louise Chapman, Matthew Michael Larg. Should clozapine be available to people with early schizophrenia and suicidal ideation? The Australian and New Zealand journal of psychiatry. vol 49. issue 4. 2016-02-19. PMID:25526942. |
should clozapine be available to people with early schizophrenia and suicidal ideation? |
2016-02-19 |
2023-08-13 |
Not clear |
| Siobhan Gee, Thomas Dixon, Mary Docherty, Sukhwinder S Shergil. Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment. BMC psychiatry. vol 15. 2016-02-19. PMID:26265348. |
clozapine is the only licensed medication for treatment-resistant schizophrenia. |
2016-02-19 |
2023-08-13 |
Not clear |
| Nancy J Butcher, Wai Lun Alan Fung, Laura Fitzpatrick, Alina Guna, Danielle M Andrade, Anthony E Lang, Eva W C Chow, Anne S Basset. Response to clozapine in a clinically identifiable subtype of schizophrenia. The British journal of psychiatry : the journal of mental science. vol 206. issue 6. 2016-02-16. PMID:25745132. |
response to clozapine in a clinically identifiable subtype of schizophrenia. |
2016-02-16 |
2023-08-13 |
Not clear |
| Carolina Schneider, Efstathios Papachristou, Theresa Wimberley, Christiane Gasse, Danai Dima, James H MacCabe, Preben Bo Mortensen, Sophia Frango. Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 6. 2016-02-16. PMID:25769917. |
clozapine use in childhood and adolescent schizophrenia: a nationwide population-based study. |
2016-02-16 |
2023-08-13 |
Not clear |
| Carolina Schneider, Efstathios Papachristou, Theresa Wimberley, Christiane Gasse, Danai Dima, James H MacCabe, Preben Bo Mortensen, Sophia Frango. Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 6. 2016-02-16. PMID:25769917. |
this study aimed to identify the predictors of clozapine use in eos and characterize the clinical profile and outcome of clozapine-treated youths with schizophrenia. |
2016-02-16 |
2023-08-13 |
Not clear |
| Carolina Schneider, Efstathios Papachristou, Theresa Wimberley, Christiane Gasse, Danai Dima, James H MacCabe, Preben Bo Mortensen, Sophia Frango. Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 6. 2016-02-16. PMID:25769917. |
we identified 662 eos cases (1.9% of all schizophrenia cases), of whom 108 (17.6%) had commenced clozapine by december 31st 2008. |
2016-02-16 |
2023-08-13 |
Not clear |
| Carolina Schneider, Efstathios Papachristou, Theresa Wimberley, Christiane Gasse, Danai Dima, James H MacCabe, Preben Bo Mortensen, Sophia Frango. Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 6. 2016-02-16. PMID:25769917. |
older age at diagnosis of schizophrenia [hr=1.2, 95% ci (1.05-1.4), p=0.01], family history of schizophrenia [hr=2.1, 95% ci (1.1-3.04), p=0.02] and attempted suicide [hr=1.8, 95% ci (1.1-3.04), p=0.02] emerged as significant predictors of clozapine use. |
2016-02-16 |
2023-08-13 |
Not clear |
| A Wysokiński, M L Kowalski, I Kłoszewsk. Serum levels of PYY(1-36) peptide in patients with schizophrenia on clozapine monotherapy. Pharmacopsychiatry. vol 47. issue 4-5. 2016-02-15. PMID:24936806. |
serum levels of pyy(1-36) peptide in patients with schizophrenia on clozapine monotherapy. |
2016-02-15 |
2023-08-13 |
Not clear |
| A Wysokiński, M L Kowalski, I Kłoszewsk. Serum levels of PYY(1-36) peptide in patients with schizophrenia on clozapine monotherapy. Pharmacopsychiatry. vol 47. issue 4-5. 2016-02-15. PMID:24936806. |
the present study was undertaken to determine if patients with schizophrenia on clozapine monotherapy have lower serum levels of peptide yy [pyy(1-36)], which is an endogenous inhibitor of food intake, comparing to healthy controls. |
2016-02-15 |
2023-08-13 |
Not clear |
| S R T Veerman, P F J Schulte, L de Haa. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry. vol 47. issue 4-5. 2016-02-15. PMID:25002292. |
glutamate agonists combined with non-clozapine antipsychotics and glutamate antagonists augmented to clozapine show interesting clinical benefits in refractory schizophrenia. |
2016-02-15 |
2023-08-13 |
Not clear |
| S R T Veerman, P F J Schulte, L de Haa. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry. vol 47. issue 4-5. 2016-02-15. PMID:25002292. |
we illustrate how unique properties of the nmda receptor antagonist memantine in addition to clozapine, may cause improvement of positive, negative and cognitive symptoms of schizophrenia. |
2016-02-15 |
2023-08-13 |
Not clear |
| Kelan L Thomas, Yawen Jiang, Jeffrey S McComb. Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 27. issue 2. 2016-02-15. PMID:25696785. |
clozapine revisited: impact of clozapine vs olanzapine on health care use by schizophrenia patients on medicaid. |
2016-02-15 |
2023-08-13 |
Not clear |
| Kelan L Thomas, Yawen Jiang, Jeffrey S McComb. Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 27. issue 2. 2016-02-15. PMID:25696785. |
our purpose was to evaluate health care use and cost patterns for clozapine compared with olanzapine in the treatment of schizophrenia. |
2016-02-15 |
2023-08-13 |
Not clear |